Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: 3 - The Real Truth

Analysts Think You Should Buy and Hold This 1 Dividend Stock ‘Forever’

Amgen stands out as a stable and attractive dividend stock, with a strong lineup of new medicines, a solid 3.45% forward yield, and a 201% dividend growth over the past decade.

Barchart

Amgen's Quarterly Earnings Preview: What You Need to Know

Amgen is scheduled to report its first-quarter results next month, and analysts expect a single-digit earnings growth.

Barchart

These 2 Buy-Rated Dividend Stocks Could Be Next in Line for a Trump Tariff Selloff. Should You Jump Ship Now?

Trump’s proposed tariffs on pharmaceutical imports from countries like Ireland and India have sparked concerns for companies like Amgen and Gilead Sciences.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

With 23andMe filing for bankruptcy, what happens to consumers’ genetic data?

The announcement that 23andMe is filing for bankruptcy and has put its genetic genealogy database up for sale has sent its customers into a bit of a privacy tizzy. On March 21, California Attorney General Bob Bonta issued a consumer alert with detailed instructions about how to delete one’s data.

The Conversation

Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?

Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market.

Barchart

Amgen Stock: Is AMGN Outperforming the Healthcare Sector?

Amgen has outperformed the healthcare sector over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

Wall Street Predicts This Dividend Stock to Soar 31%: Should You Buy The Dip Now?

Amgen stock is an attractive buy on the dip for passive income-focused investors.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Earnings Miss? Amgen’s Dividend Still a Bright Spot

AMGN stock is down over 1% despite beating revenue and earnings estimates; investors are selling the news on the company’s latest obesity drug and weak guidance

MarketBeat

Stock Index Futures Muted Ahead of U.S. JOLTs Report and Fed Speak, Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.01%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.08% this morning as investors awaited the latest reading on U.S. job openings, comments from Federal Reserve officials, and corporate earnings reports from heavyweight names.

Barchart

Stock Index Futures Slip on Trade War Concerns, U.S. JOLTs Report and Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.21%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.11% this morning as investors adopted a cautious stance after China retaliated to new U.S. tariffs.

Barchart

Are Wall Street Analysts Predicting Amgen Stock Will Climb or Sink?

Despite Amgen's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Barchart

Amgen’s Q4 2024 Earnings: What to Expect

Drug manufacturing giant Amgen is expected to announce its fourth-quarter results in the upcoming month and analysts expect single-digit growth in earnings.

Barchart

Build a Bulletproof Portfolio with These Three Diversified Dividend Stocks

Learn how diversification, careful screening, and key metrics like payout ratios and yields can help build a strong, income-generating portfolio for the long term.

Barchart

Selling Covered Calls On The Dogs Of The Dow Stocks

The Dogs of the Dow is a long standing wall street strategy for investing in the stock market that involves purchasing the 10 highest yielding Dow Jones stocks.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?

Results for Amgen's weight loss drug Maritide were highly anticipated, but fell short. However, MariTide could still turn the tables in future studies.

Barchart

Is Amgen Stock Underperforming the Dow?

Despite pharma giant Amgen trailing behind the Dow index over the past three months, analysts remain cautiously bullish about the stock's growth potential.

StockNews.com

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

Kiplinger

Stock Market Today: The S&P 500 Reclaims the 6K Level

Investors see Scott Bessent as a safe shepherd of the economy as the president-elect burnishes his "Tariff Man" reputation.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Stocks Gain on Positive Corporate News and a Jump in US Consumer Confidence

The S&P 500 Index ($SPX ) (SPY ) today is up +0.25%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.59%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.45%. Stocks today are mixed, with some positive corporate news lifting the broader market. JM...

Barchart

Stocks Climb on Positive Corporate News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.25%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.40%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.48%. Stocks today are mixed, with some positive corporate news lifting the broader market. JM...

Benzinga

Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau

Amgen's Phase 2 MariTide trial showed ~20% weight loss at 52 weeks, cardiometabolic improvements, and no significant safety issues.

Barchart

3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Barchart

Is Amgen Stock Outperforming the Nasdaq?

Amgen has surpassed the Nasdaq recently, and analysts are cautiously optimistic about its future potential.

Barchart

AMGN Bullish Diagonal Trade Targets a Price of $350 by October 18th

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place within an option portfolio.

Barchart

Are Wall Street Analysts Bullish on Amgen Stock?

Amgen has outperformed the broader market over the past year, yet Wall Street analysts remain cautiously optimistic about the stock’s prospects.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.